Industries > Pharma > Nuclear Medicine Market Report 2021-2031
Nuclear Medicine Market Report 2021-2031
Forecasts by Type (Diagnostic (SPECT - Technetium, PET- F-18), by Therapeutic (Beta Emitters – I-131, Alpha Emitters, Brachytherapy – Y-90)), by Application (Oncology, Cardiology). PLUS Profiles of Leading Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios
Nuclear Medicine/Radiopharmaceuticals Market-our new study reveals current trends, technological advancements, and predicted revenues
Where the Nuclear Medicine/Radiopharmaceuticals market is heading? If you are involved in this industry you must read this newly updated report. Visiongain’s report shows you the potential revenue streams to 2031, assessing data, trends, opportunities and business prospects there.
Discover how to stay ahead
Our 190+ page report provides 150+ tables, 150+ charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our study lets you assess forecasted sales at overall world market and regional level. See financial performance of companies, trends, opportunities, and revenue growth. Much opportunity remains in this growing Nuclear Medicine/Radiopharmaceuticals market. See how to exploit the opportunities.
Forecasts to 2031 and other analyses reveal the commercial prospects
– In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares, key player positioning, and an exhaustive product portfolio comparison of key vendors
– You find original analyses, with business outlooks and developments which would be useful to tap potential business areas for key players
– Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges, SWOT analysis), product profiles and commercial developments.
Report Scope
Global Nuclear Medicine/Radiopharmaceuticals market 2021-2031 is segmented on the basis of Product, Application and Geography.
• Revenue and growth forecasts from 2021 to 2031 for the Global Nuclear Medicine/Radiopharmaceuticals Market by Product:
– Diagnostic Products
– Diagnostic Products
– TC-99m
– TL-201
– GA-67
– I-123
– Other SPECT products
– PET
– F-18
– SR-82/RB-82
– Other PET products
– Therapeutic Products
– Alpha emitters
– RA-223
– Other alpha emitters
– Beta emitters
– I-131
– Y-90
– SM-153
– Re-186
– Lu-117
– Other beta emitters
– Brachytherapy
– Cesium-131
– Iodine-125
– Palladium-103
– Iridium-192
– Other brachytherapy products
• Revenue and growth forecasts from 2021 to 2031 for the Global Nuclear Medicine/Radiopharmaceuticals Market by Application:
– Cardiology
– Neurology
– Oncology
–Thyroid
–Lymphoma
–Bone metastasis
– Endocrine tumor
• Revenue and growth forecasts from 2021 to 2031 for the Global Nuclear Medicine/Radiopharmaceuticals Market by Region:
– North America: US, Canada
– Europe: Germany, UK, Italy, France, Spain, Rest of Europe
– Asia-Pacific: China, India, Japan, Australia, Rest of Asia-Pacific
– Latin America: Brazil, Mexico, and Rest of Latin America
– Middle East & Africa: GCC, South Africa, Rest of MEA
• Our study discusses the selected leading companies that are the major players in the Nuclear Medicine/Radiopharmaceuticals industry:
– Eckert & Ziegler
–Mallinckrodt
– Curium Pharma
– GE Healthcare
– Jubilant Pharma. LLC
– Bracco Imaging S.p.A
– Nordion (Canada) Inc.
– The Institute for Radioelements (IRE – IRE ELiT)
– Australian Nuclear Science & Technology Organization (ANSTO)
– NTP Radioisotopes SOC Ltd.
–Eczacibasi-Monrol
–Lantheus Medical Imaging, Inc.
How the Nuclear Medicine/Radiopharmaceuticals Market report helps you
In summary, our 190+ page report provides you with the following knowledge:
– Revenue forecasts to 2031 for each of the above mentioned segments each forecasted at a global and regional level– growth of all segments on regional level helps to understand most lucrative segment.
– Revenue forecasts to 2031 for 5 regional and 10 key national markets – the report highlights market growth prospects for key countries such as the U.S., Canada, Germany, UK, France, Italy, Spain, China, Japan, and India. The report also highlights growth potential in Central & South America as well as Middle East & Africa.
– Prospects for established firms and those seeking to enter the market– including company profiles for over 10 of the major companies involved in the Nuclear Medicine/Radiopharmaceuticals market
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
COVID 19 Impact & Recovery Analysis on the Market
Currently, COVID-19 (Coronavirus) is prevalent across the globe. Many companies are underway to discover a vaccine, or therapeutics which can prevent or cure the COVID-19 virus. According to the World Health Organization, as of 13th September 2020, there were over 28,637,952 confirmed cases of COVID-19, with more than 917,417 deaths, globally.
The COVID-19 disease is continuously disrupting the growth of various markets. However, the immediate effect of the pandemic is different. Some industries will register a drop in demand, various other markets will remain unchanged and display a promising growth opportunities. The healthcare centers, such as hospitals and diagnostic labs, have been investing heavily in maintaining the supply of essential equipment and drugs. Due to lockdown across the globe, people were unable to reach healthcare facilities and non-urgent procedures were advised to put hold which impacted the healthcare industry a lot.
Due to COVID 19 pandemic patients were reluctant in visiting hospitals or clinics for their treatments and preferred virtual doctor visits. Lockdown across the globe due to the pandemic led to the delay of procedures which were not urgent. These factors negatively impacted the Nuclear Medicine market for limited period of time. However, slowly the situation is getting back to normal everywhere and the market discussed is expected to increase in future.
Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Nuclear Medicine/Radiopharmaceuticals market and leading companies. You will find data, trends and predictions.
The Nuclear Medicine/Radiopharmaceuticals Market 2021-2031 report will be of value to anyone who wants to better understand the market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the Nuclear Medicine/Radiopharmaceuticals industry.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Nuclear Medicine Market Report 2021-2031: Forecasts by Type (Diagnostic (SPECT – Technetium, PET- F-18), by Therapeutic (Beta Emitters – I-131, Alpha Emitters, Brachytherapy – Y-90)), by Application (Oncology, Cardiology). PLUS Profiles of Leading Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered by This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated VISIONGAIN Reports
1.8. About VISIONGAIN
2. Introduction to the Nuclear Medicine/Radiopharmaceuticals Market
2.1. Nuclear Medicine/Radiopharmaceuticals Market Definition
2.2. Application Submarkets Definitions
2.3. Application Submarkets Definitions
2.4. Procedural Volume Assessment Submarkets Definitions
3. Nuclear Medicine/Radiopharmaceuticals Market Overview
3.1. Global Nuclear Medicine/Radiopharmaceuticals Market Size and Forecast by Region
3.2. Global Nuclear Medicine/Radiopharmaceuticals Market Share by Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Growing Rate and Prevalence of Target Situations
3.3.1.2. Alpha Radio immunotherapy-Based Beset Cancer Treatment
3.3.2. Market Restraints/Challenges
3.3.2.1. Short Half-Life of Radiopharmaceuticals
3.3.3. Opportunities
3.3.3.1. Use of Radiopharmaceuticals in Neurological Applications
3.3.4. Global Nuclear Medicine/Radiopharmaceuticals Market: Trends
3.3.4.1. Hospital Budget Cuts and High Therapeutic Nuclear Medicine Prices
3.3.5. SWOT Analysis
3.3.5.1. Strengths
3.3.5.1.1. Strength 1
3.3.5.2. Weaknesses
3.3.5.2.1. Weakness 1
3.3.5.3. Opportunities
3.3.5.3.1. Opportunity 1
3.3.5.4. Threats
3.3.5.4.1. Threat 1
3.3.6. Porter’s Five Forces Analysis
3.3.6.1. Competitive Rivalry
3.3.6.2. Supplier Power
3.3.6.3. Buyer Power
3.3.6.4. Threat of Substitution
3.3.6.5. Threat of New Entry
4. Global Nuclear Medicine/Radiopharmaceuticals Market Analysis and Forecast 2020-2030, by Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.1.1. Diagnostic Nuclear Medicine
4.1.1.1. Diagnostic Nuclear Medicine market 2021 – 2031(USD Million)
4.1.2. Therapeutic Nuclear Medicine
4.1.2.1. Therapeutic Nuclear Medicine market 2021 – 2031 (USD Million)
5. Global Nuclear Medicine/Radiopharmaceuticals Market Analysis and Forecast, 2020-2030 by Application(Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Diagnostic Applications
5.1.1.1. Diagnostic Applications market (USD Million)
5.1.2. Therapeutic Applications
5.1.2.1. Therapeutic Applications market (USD Million)
6. Global Nuclear Medicine/Radiopharmaceuticals Market Analysis and Forecast, 2020-2030 byProcedural Volume Assessment (Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.1.1. Diagnostic Procedures
6.1.1.1. Diagnostic Procedures market (USD Million)
6.1.2. Therapeutic Procedures
6.1.2.1. Therapeutic Procedures
7. North America Nuclear Medicine/Radiopharmaceuticals Market Analysis and Forecast, 2020-2030 Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.2. North America Nuclear Medicine/Radiopharmaceuticals Market Size and Forecast byType
7.3. North America Nuclear Medicine/Radiopharmaceuticals Market Size and Forecast byApplication
7.4. North America Nuclear Medicine/Radiopharmaceuticals Market Size and Forecast byProcedural Volume Assessment
7.5. U.S. Nuclear Medicine/Radiopharmaceuticals Market
7.6. Canada Nuclear Medicine/Radiopharmaceuticals Market
8. Europe Nuclear Medicine/Radiopharmaceuticals Market Analysis and Forecast, 2020-2030 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.2. Europe Nuclear Medicine/Radiopharmaceuticals Market Size and Forecast by Type
8.3. Europe Nuclear Medicine/Radiopharmaceuticals Market Size and Forecast by Application
8.4. Europe Nuclear Medicine/Radiopharmaceuticals Market Size and Forecast by Procedural Volume Assessment
8.5. UK Nuclear Medicine/Radiopharmaceuticals Market
8.6. Germany Nuclear Medicine/Radiopharmaceuticals Market
8.7. France Nuclear Medicine/Radiopharmaceuticals Market
8.8. Rest of Europe Nuclear Medicine/Radiopharmaceuticals Market
9. Asia Pacific Nuclear Medicine/Radiopharmaceuticals Market Analysis and Forecast, 2020-2030 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.2. Asia Pacific Nuclear Medicine/Radiopharmaceuticals Market Size and Forecast by Type
9.3. Asia Pacific Nuclear Medicine/Radiopharmaceuticals Market Size and Forecast by Application
9.4. Asia Pacific Nuclear Medicine/Radiopharmaceuticals Market Size and Forecast by Procedural Volume Assessment
9.5. China Nuclear Medicine/Radiopharmaceuticals Market
9.6. India Nuclear Medicine/Radiopharmaceuticals Market
9.7. Japan Nuclear Medicine/Radiopharmaceuticals Market
9.8. Rest of Asia Pacific Nuclear Medicine/Radiopharmaceuticals Market
10. Latin America Nuclear Medicine/Radiopharmaceuticals Market Analysis and Forecast, 2020-2030 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.2. Latin America Nuclear Medicine/Radiopharmaceuticals Market Size and Forecast by Type
10.3. Latin America Nuclear Medicine/Radiopharmaceuticals Market Size and Forecast by Application
10.4. Latin America Nuclear Medicine/Radiopharmaceuticals Market Size and Forecast by Procedural Volume Assessment
10.5. Brazil Nuclear Medicine/Radiopharmaceuticals Market
10.6. Mexico Nuclear Medicine/Radiopharmaceuticals Market
10.7. Rest of Latin America Nuclear Medicine/Radiopharmaceuticals Market
11. MEA Nuclear Medicine/Radiopharmaceuticals Market Analysis and Forecast, 2020-2030 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
11.1. Market Overview
11.2. MEA Nuclear Medicine/Radiopharmaceuticals Market Size and Forecast by Type
11.3. MEA Nuclear Medicine/Radiopharmaceuticals Market Size and Forecast by Application
11.4. MEA Nuclear Medicine/Radiopharmaceuticals Market Size and Forecast by Procedural Volume Assessment
11.5. GCC Nuclear Medicine/Radiopharmaceuticals Market
11.6. South Africa Nuclear Medicine/Radiopharmaceuticals Market
11.7. Rest of MEA Nuclear Medicine/Radiopharmaceuticals Market
12. Companies in the Nuclear Medicine/Radiopharmaceuticals Market
12.1. Cardinal Health
12.1.1. Company Snapshot
12.1.2. Company Overview
12.1.3. Financial Performance (2015-2019)
12.1.3.1. Net Revenue
12.1.3.2. Gross Profit
12.1.3.3. Geographical Revenue, 2019
12.1.4. Application Offerings
12.1.5. Recent Initiatives (2017-2019)
12.2. Curium.
12.2.1. Company Snapshot
12.2.2. Company Overview
12.2.3. Financial Performance (2015-2019)
12.2.3.1. Net Revenue
12.2.3.2. Gross Profit
12.2.3.3. Geographical Revenue, 2019
12.2.4. Application Offerings
12.2.5. Recent Initiatives (2017-2019)
12.3. GE Healthcare
12.3.1. Company Snapshot
12.3.2. Company Overview
12.3.3. Financial Performance (2015-2019)
12.3.3.1. Net Revenue
12.3.3.2. Gross Profit
12.3.3.3. Geographical Revenue, 2019
12.3.4. Application Offerings
12.3.5. Recent Initiatives (2017-2019)
12.4. Lantheus Medical Imaging, Inc
12.4.1. Company Snapshot
12.4.2. Company Overview
12.4.3. Financial Performance (2015-2019)
12.4.3.1. Net Revenue
12.4.3.2. Gross Profit
12.4.3.3. Geographical Revenue, 2019
12.4.4. Application Offerings
12.4.5. Recent Initiatives (2017-2019)
12.5. Bayer AG
12.5.1. Company Snapshot
12.5.2. Company Overview
12.5.3. Financial Performance (2015-2019)
12.5.3.1. Net Revenue
12.5.3.2. Gross Profit
12.5.3.3. Geographical Revenue, 2019
12.5.4. Application Offerings
12.5.5. Recent Initiatives (2017-2019)
12.6. Bracco Imaging S.P.A
12.6.1. Company Snapshot
12.6.2. Company Overview
12.6.3. Financial Performance (2015-2019)
12.6.3.1. Net Revenue
12.6.3.2. Gross Profit
12.6.3.3. Geographical Revenue, 2019
12.6.4. Application Offerings
12.6.5. Recent Initiatives (2017-2019)
12.7. Nordion, Inc. (A Subsidiary of Sterigenics International)
12.7.1. Company Snapshot
12.7.2. Company Overview
12.7.3. Financial Performance (2015-2019)
12.7.3.1. Net Revenue
12.7.3.2. Gross Profit
12.7.3.3. Geographical Revenue, 2019
12.7.4. Application Offerings
12.7.5. Recent Initiatives (2017-2019)
12.8. Joint Stock Company Isotope (Jsc Isotope).
12.8.1. Company Snapshot
12.8.2. Company Overview
12.8.3. Financial Performance (2015-2019)
12.8.3.1. Net Revenue
12.8.3.2. Gross Profit
12.8.3.3. Geographical Revenue, 2019
12.8.4. Application Offerings
12.8.5. Recent Initiatives (2017-2019)
12.9. Sinotau Pharmaceuticals Group
12.9.1. Company Snapshot
12.9.2. Company Overview
12.9.3. Financial Performance (2015-2019)
12.9.3.1. Net Revenue
12.9.3.2. Gross Profit
12.9.3.3. Geographical Revenue, 2019
12.9.4. Application Offerings
12.9.5. Recent Initiatives (2017-2019)
12.10. Jubilant Draximage, Inc. (A Subsidiary of Jubilant Pharma)
12.10.1. Company Snapshot
12.10.2. Company Overview
12.10.3. Financial Performance (2015-2019)
12.10.3.1. Net Revenue
12.10.3.2. Gross Profit
12.10.3.3. Geographical Revenue, 2019
12.10.4. Application Offerings
12.10.5. Recent Initiatives (2017-2019)
12.11. Other Notable Players
13. Conclusion
14. Glossary
Associated VISIONGAIN Reports
VISIONGAIN Report Sales Order Form
Appendix A
About VISIONGAIN
Appendix B
VISIONGAIN report evaluation form
LIST OF TABLES
Table No 1: Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$Mn, AGR %, CAGR %) (Before COVID)
Table No 2: Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 3: Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 4: Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 5: Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 6: Nuclear Medicine/Radiopharmaceuticals Market Drivers & Restraints 2020
Table No 7: Nuclear Medicine/Radiopharmaceuticals Forecast by Type 2020-2030 (US$M, AGR %, CAGR %) (Before COVID)
Table No 8: Nuclear Medicine/Radiopharmaceuticals Forecast by Type 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 9: Nuclear Medicine/Radiopharmaceuticals Forecast by Type 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 10: Nuclear Medicine/Radiopharmaceuticals Forecast by Type 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 11: Nuclear Medicine/Radiopharmaceuticals Forecast by Type 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 12: Diagnostic Nuclear Medicine Submarket Forecast 2020-2030 (US$Mn, AGR %, CAGR %) (Before COVID)
Table No 13: Diagnostic Nuclear Medicine Submarket Forecast 2020-2030 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 14: Diagnostic Nuclear Medicine Submarket Forecast 2020-2030 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 15: Diagnostic Nuclear Medicine Submarket Forecast 2020-2030 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 16: Diagnostic Nuclear Medicine Submarket Forecast 2020-2030 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 17: Therapeutic Nuclear Medicine Submarket Forecast 2020-2030 (US$Mn, AGR %, CAGR %) (Before COVID)
Table No 18: Therapeutic Nuclear Medicine Submarket Forecast 2020-2030 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 19: Therapeutic Nuclear Medicine Submarket Forecast 2020-2030 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 20: Therapeutic Nuclear Medicine Submarket Forecast 2020-2030 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 21: Therapeutic Nuclear Medicine Submarket Forecast 2020-2030 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 22: Nuclear Medicine/Radiopharmaceuticals Submarket Forecast by Application 2020-2030 (US$M, AGR %, CAGR %) (Before COVID)
Table No 23: Nuclear Medicine/Radiopharmaceuticals Submarket Forecast by Application 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 24: Nuclear Medicine/Radiopharmaceuticals Submarket Forecast by Application 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 25: Nuclear Medicine/Radiopharmaceuticals Submarket Forecast by Application 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 26: Nuclear Medicine/Radiopharmaceuticals Submarket Forecast by Application 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 27: Diagnostic Applications Submarket Forecast 2020-2030 (US$M, AGR %, CAGR %) (Before COVID)
Table No 28: Diagnostic Applications Submarket Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 29: Diagnostic Applications Submarket Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 30: Diagnostic Applications Submarket Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 31: Diagnostic Applications Submarket Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 32: Therapeutic Applications Submarket Forecast 2020-2030 (US$M, AGR %, CAGR %) (Before COVID)
Table No 33: Therapeutic Applications Submarket Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 34: Therapeutic Applications Submarket Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 35: Therapeutic Applications Submarket Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 36: Therapeutic Applications Submarket Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 37: Nuclear Medicine/Radiopharmaceuticals Forecast by Procedural Volume Assessment 2020-2030 (US$M, AGR %, CAGR %) (Before COVID)
Table No 38: Nuclear Medicine/Radiopharmaceuticals Forecast by Procedural Volume Assessment 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 39: Nuclear Medicine/Radiopharmaceuticals Forecast by Procedural Volume Assessment 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 40: Nuclear Medicine/Radiopharmaceuticals Forecast by Procedural Volume Assessment 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 41: Nuclear Medicine/Radiopharmaceuticals Forecast by Procedural Volume Assessment 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 42: Diagnostic Procedures Submarket Forecast 2020-2030 (US$Mn, AGR %, CAGR %) (Before COVID)
Table No 43: Diagnostic Procedures Submarket Forecast 2020-2030 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 44: Diagnostic Procedures Submarket Forecast 2020-2030 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 45: Diagnostic Procedures Submarket Forecast 2020-2030 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 46: Diagnostic Procedures Submarket Forecast 2020-2030 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 47: Therapeutic Procedures Submarket Forecast 2020-2030 (US$Mn, AGR %, CAGR %) (Before COVID)
Table No 48: Therapeutic Procedures Submarket Forecast 2020-2030 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 49: Therapeutic Procedures Submarket Forecast 2020-2030 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 50: Therapeutic Procedures Submarket Forecast 2020-2030 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 51: Therapeutic Procedures Submarket Forecast 2020-2030 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 52: Therapeutic ProceduresI Submarket Forecast 2020-2030 (US$Mn, AGR %, CAGR %) (Before COVID)
Table No 53: Therapeutic ProceduresI Submarket Forecast 2020-2030 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table No 54: Therapeutic ProceduresI Submarket Forecast 2020-2030 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table No 55: Therapeutic ProceduresI Submarket Forecast 2020-2030 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table No 56: Therapeutic ProceduresI Submarket Forecast 2020-2030 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table No 57: Regional Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (Before COVID)
Table No 58: Regional Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 59: Regional Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 60: Regional Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 61: Regional Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 62: North America Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M, AGR %, CAGR %) (Before COVID)
Table No 63: North America Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 64: North America Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 65: North America Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 66: North America Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 67: North America Nuclear Medicine/Radiopharmaceuticals Market Forecast by Application 2020-2030 (US$M, AGR %, CAGR %) (Before COVID)
Table No 68: North America Nuclear Medicine/Radiopharmaceuticals Market Forecast by Application 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 69: North America Nuclear Medicine/Radiopharmaceuticals Market Forecast by Application 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 70: North America Nuclear Medicine/Radiopharmaceuticals Market Forecast by Application 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 71: North America Nuclear Medicine/Radiopharmaceuticals Market Forecast by Application 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 72: North America Nuclear Medicine/Radiopharmaceuticals Market Forecast by Procedural Volume Assessment 2020-2030 (US$M, AGR %, CAGR %) (Before COVID)
Table No 73: North America Nuclear Medicine/Radiopharmaceuticals Market Forecast by Procedural Volume Assessment 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 74: North America Nuclear Medicine/Radiopharmaceuticals Market Forecast by Procedural Volume Assessment 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 75: North America Nuclear Medicine/Radiopharmaceuticals Market Forecast by Procedural Volume Assessment 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 76: North America Nuclear Medicine/Radiopharmaceuticals Market Forecast by Procedural Volume Assessment 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 77: US Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (Before COVID)
Table No 78: US Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 79: US Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 80: US Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 81: US Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 82: Canada Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (Before COVID)
Table No 83: Canada Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 84: Canada Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 85: Canada Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 86: Canada Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 87: Europe Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M, AGR %, CAGR %) (Before COVID)
Table No 88: Europe Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 89: Europe Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 90: Europe Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 91: Europe Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 92: Europe Nuclear Medicine/Radiopharmaceuticals Market Forecast by Application 2020-2030 (US$M, AGR %, CAGR %) (Before COVID)
Table No 93: Europe Nuclear Medicine/Radiopharmaceuticals Market Forecast by Application 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 94: Europe Nuclear Medicine/Radiopharmaceuticals Market Forecast by Application 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 95: Europe Nuclear Medicine/Radiopharmaceuticals Market Forecast by Application 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 96: Europe Nuclear Medicine/Radiopharmaceuticals Market Forecast by Application 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 97: Europe Nuclear Medicine/Radiopharmaceuticals Market Forecast by Procedural Volume Assessment 2020-2030 (US$M, AGR %, CAGR %) (Before COVID)
Table No 98: Europe Nuclear Medicine/Radiopharmaceuticals Market Forecast by Procedural Volume Assessment 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 99: Europe Nuclear Medicine/Radiopharmaceuticals Market Forecast by Procedural Volume Assessment 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 100: Europe Nuclear Medicine/Radiopharmaceuticals Market Forecast by Procedural Volume Assessment 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 101: Europe Nuclear Medicine/Radiopharmaceuticals Market Forecast by Procedural Volume Assessment 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 102: UK Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (Before COVID)
Table No 103: UK Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 104: UK Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 105: UK Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 106: UK Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 107: Germany Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (Before COVID)
Table No 108: Germany Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 109: Germany Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 110: Germany Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 111: Germany Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 112: France Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (Before COVID)
Table No 113: France Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 114: France Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 115: France Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 116: France Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 117: Rest of Europe Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (Before COVID)
Table No 118: Rest of Europe Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 119: Rest of Europe Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 120: Rest of Europe Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 121: Rest of Europe Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 122: Asia Pacific Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M, AGR %, CAGR %) (Before COVID)
Table No 123: Asia Pacific Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 124: Asia Pacific Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 125: Asia Pacific Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 126: Asia Pacific Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 127: Asia Pacific Nuclear Medicine/Radiopharmaceuticals Market Forecast by Application 2020-2030 (US$M, AGR %, CAGR %) (Before COVID)
Table No 128: Asia Pacific Nuclear Medicine/Radiopharmaceuticals Market Forecast by Application 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 129: Asia Pacific Nuclear Medicine/Radiopharmaceuticals Market Forecast by Application 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 130: Asia Pacific Nuclear Medicine/Radiopharmaceuticals Market Forecast by Application 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 131: Asia Pacific Nuclear Medicine/Radiopharmaceuticals Market Forecast by Application 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 132: Asia Pacific Nuclear Medicine/Radiopharmaceuticals Market Forecast by Procedural Volume Assessment 2020-2030 (US$M, AGR %, CAGR %) (Before COVID)
Table No 133: Asia Pacific Nuclear Medicine/Radiopharmaceuticals Market Forecast by Procedural Volume Assessment 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 134: Asia Pacific Nuclear Medicine/Radiopharmaceuticals Market Forecast by Procedural Volume Assessment 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 135: Asia Pacific Nuclear Medicine/Radiopharmaceuticals Market Forecast by Procedural Volume Assessment 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 136: Asia Pacific Nuclear Medicine/Radiopharmaceuticals Market Forecast by Procedural Volume Assessment 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 137: China Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (Before COVID)
Table No 138: China Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 139: China Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 140: China Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 141: China Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 142: India Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (Before COVID)
Table No 143: India Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 144: India Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 145: India Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 146: India Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 147: India Military Aircraft Fleet (Aircraft Type, Number of Aircraft)
Table No 148: Japan Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (Before COVID)
Table No 149: Japan Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 150: Japan Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 151: Japan Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 152: Japan Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 153: Japan Military Aircraft Fleet (Aircraft Type, Number of Aircraft)
Table No 154: RoAPAC Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (Before COVID)
Table No 155: RoAPAC Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 156: RoAPAC Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 157: RoAPAC Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 158: RoAPAC Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 159: Latin America Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M, AGR %, CAGR %) (Before COVID)
Table No 160: Latin America Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 161: Latin America Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 162: Latin America Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 163: Latin America Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 164: Latin America Nuclear Medicine/Radiopharmaceuticals Market Forecast by Application 2020-2030 (US$M, AGR %, CAGR %) (Before COVID)
Table No 165: Latin America Nuclear Medicine/Radiopharmaceuticals Market Forecast by Application 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 166: Latin America Nuclear Medicine/Radiopharmaceuticals Market Forecast by Application 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 167: Latin America Nuclear Medicine/Radiopharmaceuticals Market Forecast by Application 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 168: Latin America Nuclear Medicine/Radiopharmaceuticals Market Forecast by Application 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 169: Latin America Nuclear Medicine/Radiopharmaceuticals Market Forecast by Procedural Volume Assessment 2020-2030 (US$M, AGR %, CAGR %) (Before COVID)
Table No 170: Latin America Nuclear Medicine/Radiopharmaceuticals Market Forecast by Procedural Volume Assessment 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 171: Latin America Nuclear Medicine/Radiopharmaceuticals Market Forecast by Procedural Volume Assessment 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 172: Latin America Nuclear Medicine/Radiopharmaceuticals Market Forecast by Procedural Volume Assessment 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 173: Latin America Nuclear Medicine/Radiopharmaceuticals Market Forecast by Procedural Volume Assessment 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 174: Brazil Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (Before COVID)
Table No 175: Brazil Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 176: Brazil Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 177: Brazil Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 178: Brazil Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 179: Mexico Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (Before COVID)
Table No 180: Mexico Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 181: Mexico Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 182: Mexico Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 183: Mexico Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 184: Rest of Latin America Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (Before COVID)
Table No 185: Rest of Latin America Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 186: Rest of Latin America Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 187: Rest of Latin America Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 188: Rest of Latin America Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 189: Middle East Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M, AGR %, CAGR %) (Before COVID)
Table No 190: Middle East Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 191: Middle East Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 192: Middle East Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 193: Middle East Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 194: Middle East Nuclear Medicine/Radiopharmaceuticals Market Forecast by Application 2020-2030 (US$M, AGR %, CAGR %) (Before COVID)
Table No 195: Middle East Nuclear Medicine/Radiopharmaceuticals Market Forecast by Application 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 196: Middle East Nuclear Medicine/Radiopharmaceuticals Market Forecast by Application 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 197: Middle East Nuclear Medicine/Radiopharmaceuticals Market Forecast by Application 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 198: Middle East Nuclear Medicine/Radiopharmaceuticals Market Forecast by Application 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 199: Middle East Nuclear Medicine/Radiopharmaceuticals Market Forecast by Procedural Volume Assessment 2020-2030 (US$M, AGR %, CAGR %) (Before COVID)
Table No 200: Middle East Nuclear Medicine/Radiopharmaceuticals Market Forecast by Procedural Volume Assessment 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 201: Middle East Nuclear Medicine/Radiopharmaceuticals Market Forecast by Procedural Volume Assessment 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 202: Middle East Nuclear Medicine/Radiopharmaceuticals Market Forecast by Procedural Volume Assessment 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 203: Middle East Nuclear Medicine/Radiopharmaceuticals Market Forecast by Procedural Volume Assessment 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 204: GCC Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (Before COVID)
Table No 205: GCC Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 206: GCC Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 207: GCC Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 208: GCC Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 209: South Africa Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (Before COVID)
Table No 210: South Africa Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 211: South Africa Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 212: South Africa Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 213: South Africa Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 214: Rest of MEA Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (Before COVID)
Table No 215: Rest of MEA Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table No 216: Rest of MEA Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table No 217: Rest of MEA Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table No 218: Rest of MEA Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table No 219: Leading 10 Fiber Optic Network Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table No 220: Cardinal Health. Profile (CEO, HQ, Founded, Website)
Table No 221: Cardinal Health. (Total Company Sales 2016-2019 (US$mn, AGR %)
Table No 222: Cardinal Health. (Net Income 2016-2019 (US$mn, AGR %)
Table No 223: Curium Profile (CEO, HQ, Founded, Website)
Table No 224: Curium (Total Company Sales 2016-2019 (US$mn, AGR %)
Table No 225: Curium (Net Income 2016-2019 (US$mn, AGR %)
Table No 226: GE Healthcare Profile (CEO, HQ, Founded, Website)
Table No 227: GE Healthcare (Total Company Sales 2016-2019 (US$mn, AGR %)
Table No 228: GE Healthcare (Net Income 2016-2019 (US$mn, AGR %)
Table No 229: Lantheus Medical Imaging, Inc. Profile (CEO, HQ, Founded, Website)
Table No 230: Lantheus Medical Imaging, Inc. (Total Company Sales 2016-2019 (US$mn, AGR %)
Table No 231: Lantheus Medical Imaging, Inc. (Net Income 2016-2019 (US$mn, AGR %))
Table No 232: Bayer AG Profile (CEO, HQ, Founded, Website)
Table No 233: Bayer AG Profile (Total Company Sales 2016-2019 (US$mn, AGR %)
Table No 234: Bayer AG Profile (Net Income 2016-2019 (US$mn, AGR %))
Table No 235: Bracco Imaging S.P.A Profile (CEO, HQ, Founded, Website)
Table No 236: Bracco Imaging S.P.A (Total Company Sales 2016-2019 (US$mn, AGR %))
Table No 237: Bracco Imaging S.P.A (Net Income 2016-2019 (US$mn, AGR %))
Table No 238: Nordion, Inc. (A Subsidiary of Sterigenics International) Profile (CEO, HQ, Founded, Website)
Table No 239: Nordion, Inc. (A Subsidiary of Sterigenics International) (Total Company Sales 2016-2019 (US$mn, AGR %))
Table No 240: Nordion, Inc. (A Subsidiary of Sterigenics International) (Net Income 2016-2019 (US$mn, AGR %))
Table No 241: Joint Stock Company Isotope (Jsc Isotope) Profile (CEO, HQ, Founded, Website)
Table No 242: Joint Stock Company Isotope (Jsc Isotope) (Total Company Sales 2016-2019 (US$mn, AGR %))
Table No 243: Joint Stock Company Isotope (Jsc Isotope) (Net Income 2016-2019 (US$mn, AGR %))
Table No 244: Joint Stock Company Isotope (Jsc Isotope) (CEO, HQ, Founded, Website)
Table No 245: Joint Stock Company Isotope (Jsc Isotope) (Total Company Sales 2016-2019 (US$mn, AGR %))
Table No 246: Joint Stock Company Isotope (Jsc Isotope) (Net Income 2016-2019 (US$mn, AGR %))
Table No 247: Sinotau Pharmaceuticals Group Profile (CEO, HQ, Founded, Website)
Table No 248: Sinotau Pharmaceuticals Group (Total Company Sales 2016-2019 (US$mn, AGR %))
Table No 249: Sinotau Pharmaceuticals Group (Net Income 2016-2019 (US$mn, AGR %))
Table No 250: Jubilant Draximage, Inc. (A Subsidiary of Jubilant Pharma) Profile (CEO, HQ, Founded, Website)
Table No 251: Jubilant Draximage, Inc. (A Subsidiary of Jubilant Pharma) (Total Company Sales 2016-2019 (US$mn, AGR %))
Table No 252: Jubilant Draximage, Inc. (A Subsidiary of Jubilant Pharma) (Net Income 2016-2019 (US$mn, AGR %))
Table No 253: Other Companies Nuclear Medicine/Radiopharmaceuticals Market 2020 (Company, Location)
LIST OF FIGURES
Figure No 1: Nuclear Medicine/Radiopharmaceuticals Market Type Overview
Figure No 2 : Nuclear Medicine/Radiopharmaceuticals Market Application Overview
Figure No 3 : Nuclear Medicine/Radiopharmaceuticals Market Procedural Volume Assessment Overview
Figure No 4 : Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %) (Before COVID)
Figure No 5 : Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %) (COVID - Scenario V)
Figure No 6 : Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %) (COVID - Scenario U)
Figure No 7 : Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %) (COVID - Scenario W)
Figure No 8 : Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %) (COVID - Scenario L)
Figure No 9 : Nuclear Medicine/Radiopharmaceuticals Submarket Forecast by Type 2020-2030 (US$M, Global AGR %) (Before COVID)
Figure No 10 : Nuclear Medicine/Radiopharmaceuticals Submarket Forecast by Type 2020-2030 (US$M, Global AGR %) (COVID - Scenario V)
Figure No 11 : Nuclear Medicine/Radiopharmaceuticals Submarket Forecast by Type 2020-2030 (US$M, Global AGR %) (COVID - Scenario U)
Figure No 12 : Nuclear Medicine/Radiopharmaceuticals Submarket Forecast by Type 2020-2030 (US$M, Global AGR %) (COVID - Scenario W)
Figure No 13 : Nuclear Medicine/Radiopharmaceuticals Submarket Forecast by Type 2020-2030 (US$M, Global AGR %) (COVID - Scenario L)
Figure No 14 : Diagnostic Nuclear Medicine 2020-2030 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure No 15 : Diagnostic Nuclear Medicine 2020-2030 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure No 16 : Diagnostic Nuclear Medicine 2020-2030 (US$M, Global AGR %) (COVID - Scenario U)
Figure No 17 : Diagnostic Nuclear Medicine 2020-2030 (US$M, Global AGR %) (COVID - Scenario W)
Figure No 18 : Diagnostic Nuclear Medicine 2020-2030 (US$M, Global AGR %) (COVID - Scenario L)
Figure No 19 : Therapeutic Nuclear Medicine Submarket Forecast 2020-2030 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure No 20 : Therapeutic Nuclear Medicine Submarket Forecast 2020-2030 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure No 21 : Therapeutic Nuclear Medicine Submarket Forecast 2020-2030 (US$M, Global AGR %) (COVID - Scenario U)
Figure No 22 : Therapeutic Nuclear Medicine Submarket Forecast 2020-2030 (US$M, Global AGR %) (COVID - Scenario W)
Figure No 23 : Therapeutic Nuclear Medicine Submarket Forecast 2020-2030 (US$M, Global AGR %) (COVID - Scenario L)
Figure No 24 : Nuclear Medicine/Radiopharmaceuticals Submarket Forecast by Application 2020-2030 (US$M, Global AGR %) (Before COVID)
Figure No 25 : Nuclear Medicine/Radiopharmaceuticals Submarket Forecast by Application 2020-2030 (US$M, Global AGR %) (COVID - Scenario V)
Figure No 26 : Nuclear Medicine/Radiopharmaceuticals Submarket Forecast by Application 2020-2030 (US$M, Global AGR %) (COVID - Scenario U)
Figure No 27 : Nuclear Medicine/Radiopharmaceuticals Submarket Forecast by Application 2020-2030 (US$M, Global AGR %) (COVID - Scenario W)
Figure No 28 : Nuclear Medicine/Radiopharmaceuticals Submarket Forecast by Application 2020-2030 (US$M, Global AGR %) (COVID - Scenario L)
Figure No 29 : Diagnostic Procedures Forecast 2020-2030 (US$M, Global AGR %) (Before COVID)
Figure No 30 : Diagnostic Procedures Forecast 2020-2030 (US$M, Global AGR %) (COVID - Scenario V)
Figure No 31 : Diagnostic Procedures Forecast 2020-2030 (US$M, Global AGR %) (COVID - Scenario U)
Figure No 32 : Diagnostic Procedures Forecast 2020-2030 (US$M, Global AGR %) (COVID - Scenario W)
Figure No 33 : Diagnostic Procedures Forecast 2020-2030 (US$M, Global AGR %) (COVID - Scenario L)
Figure No 34 : Therapeutic Procedures Submarket Forecast 2020-2030 (US$M, Global AGR %) (Before COVID)
Figure No 35 : Therapeutic Procedures Submarket Forecast 2020-2030 (US$M, Global AGR %) (COVID - Scenario V)
Figure No 36 : Therapeutic Procedures Submarket Forecast 2020-2030 (US$M, Global AGR %) (COVID - Scenario U)
Figure No 37 : Therapeutic Procedures Submarket Forecast 2020-2030 (US$M, Global AGR %) (COVID - Scenario W)
Figure No 38 : Therapeutic Procedures Submarket Forecast 2020-2030 (US$M, Global AGR %) (COVID - Scenario L)
Figure No 39 : Therapeutic ProceduresI Submarket Forecast 2020-2030 (US$M, Global AGR %) (Before COVID)
Figure No 40 : Therapeutic ProceduresI Submarket Forecast 2020-2030 (US$M, Global AGR %) (COVID - Scenario V)
Figure No 41 : Therapeutic ProceduresI Submarket Forecast 2020-2030 (US$M, Global AGR %) (COVID - Scenario U)
Figure No 42 : Therapeutic ProceduresI Submarket Forecast 2020-2030 (US$M, Global AGR %) (COVID - Scenario W)
Figure No 43 : Therapeutic ProceduresI Submarket Forecast 2020-2030 (US$M, Global AGR %) (COVID - Scenario L)
Figure No 44 : Nuclear Medicine/Radiopharmaceuticals Submarket Forecast by Procedural Volume Assessment 2020-2030 (US$M, Global AGR %) (Before COVID)
Figure No 45 : Nuclear Medicine/Radiopharmaceuticals Submarket Forecast by Procedural Volume Assessment 2020-2030 (US$M, Global AGR %) (COVID - Scenario V)
Figure No 46 : Nuclear Medicine/Radiopharmaceuticals Submarket Forecast by Procedural Volume Assessment 2020-2030 (US$M, Global AGR %) (COVID - Scenario U)
Figure No 47 : Nuclear Medicine/Radiopharmaceuticals Submarket Forecast by Procedural Volume Assessment 2020-2030 (US$M, Global AGR %) (COVID - Scenario W)
Figure No 48 : Nuclear Medicine/Radiopharmaceuticals Submarket Forecast by Procedural Volume Assessment 2020-2030 (US$M, Global AGR %) (COVID - Scenario L)
Figure No 49 : Diagnostic Procedures Submarket Forecast 2020-2030 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure No 50 : Diagnostic Procedures Submarket Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure No 51 : Diagnostic Procedures Submarket Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure No 52 : Diagnostic Procedures Submarket Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure No 53 : Diagnostic Procedures Submarket Forecast 2020-2030 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure No 54 : Therapeutic Procedures Submarket Forecast 2020-2030 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure No 55 : Therapeutic Procedures Submarket Forecast 2020-2030 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure No 56 : Therapeutic Procedures Submarket Forecast 2020-2030 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure No 57 : Therapeutic Procedures Submarket Forecast 2020-2030 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure No 58 : Therapeutic Procedures Submarket Forecast 2020-2030 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure No 59 : Regional Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (Sales US$M, Global AGR %)
Figure No 60 : Regional Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (Sales US$M, Global AGR %) (COVID - Scenario V)
Figure No 61 : Regional Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (Sales US$M, Global AGR %) (COVID - Scenario U)
Figure No 62 : Regional Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (Sales US$M, Global AGR %) (COVID - Scenario W)
Figure No 63 : Regional Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (Sales US$M, Global AGR %) (COVID - Scenario L)
Figure No 64 : North America Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M, AGR %) (Before COVID)
Figure No 65 : North America Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M, AGR %) (COVID - Scenario V)
Figure No 66 : North America Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M, AGR %) (COVID - Scenario U)
Figure No 67 : North America Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M, AGR %) (COVID - Scenario W)
Figure No 68 : North America Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M, AGR %) (COVID - Scenario L)
Figure No 69 : North America Nuclear Medicine/Radiopharmaceuticals Market Forecast by Application 2020-2030 (US$M, AGR %)
Figure No 70 : North America Nuclear Medicine/Radiopharmaceuticals Market Forecast by Application 2020-2030 (US$M, AGR %) (COVID - Scenario V)
Figure No 71 : North America Nuclear Medicine/Radiopharmaceuticals Market Forecast by Application 2020-2030 (US$M, AGR %) (COVID - Scenario U)
Figure No 72 : North America Nuclear Medicine/Radiopharmaceuticals Market Forecast by Application 2020-2030 (US$M, AGR %) (COVID - Scenario W)
Figure No 73 : North America Nuclear Medicine/Radiopharmaceuticals Market Forecast by Application 2020-2030 (US$M, AGR %) (COVID - Scenario L)
Figure No 74 : North America Nuclear Medicine/Radiopharmaceuticals Market Forecast by Procedural Volume Assessment 2020-2030 (US$M, AGR %) (Before COVID)
Figure No 75 : North America Nuclear Medicine/Radiopharmaceuticals Market Forecast by Procedural Volume Assessment 2020-2030 (US$M, AGR %) (COVID - Scenario V)
Figure No 76 : North America Nuclear Medicine/Radiopharmaceuticals Market Forecast by Procedural Volume Assessment 2020-2030 (US$M, AGR %) (COVID - Scenario U)
Figure No 77 : North America Nuclear Medicine/Radiopharmaceuticals Market Forecast by Procedural Volume Assessment 2020-2030 (US$M, AGR %) (COVID - Scenario W)
Figure No 78 : North America Nuclear Medicine/Radiopharmaceuticals Market Forecast by Procedural Volume Assessment 2020-2030 (US$M, AGR %) (COVID - Scenario L)
Figure No 79 : US Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %) (Before COVID)
Figure No 80 : US Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %) (COVID - Scenario V)
Figure No 81 : US Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %) (COVID - Scenario U)
Figure No 82 : US Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %) (COVID - Scenario W)
Figure No 83 : US Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %) (COVID - Scenario L)
Figure No 84 : Canada Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %)
Figure No 85 : Canada Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %) (COVID - Scenario V)
Figure No 86 : Canada Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %) (COVID - Scenario U)
Figure No 87 : Canada Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %) (COVID - Scenario W)
Figure No 88 : Canada Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %) (COVID - Scenario L)
Figure No 89 : Europe Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M) (Before COVID)
Figure No 90 : Europe Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M) (COVID - Scenario V)
Figure No 91 : Europe Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M) (COVID - Scenario U)
Figure No 92 : Europe Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M) (COVID - Scenario W)
Figure No 93 : Europe Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M) (COVID - Scenario L)
Figure No 94 : Europe Nuclear Medicine/Radiopharmaceuticals Market Forecast by Application 2020-2030 (US$M) (Before COVID)
Figure No 95 : Europe Nuclear Medicine/Radiopharmaceuticals Market Forecast by Application 2020-2030 (US$M) (COVID - Scenario V)
Figure No 96 : Europe Nuclear Medicine/Radiopharmaceuticals Market Forecast by Application 2020-2030 (US$M) (COVID - Scenario U)
Figure No 97 : Europe Nuclear Medicine/Radiopharmaceuticals Market Forecast by Application 2020-2030 (US$M) (COVID - Scenario W)
Figure No 98 : Europe Nuclear Medicine/Radiopharmaceuticals Market Forecast by Application 2020-2030 (US$M) (COVID - Scenario L)
Figure No 99 : Europe Nuclear Medicine/Radiopharmaceuticals Market Forecast by Procedural Volume Assessment 2020-2030 (US$M, Global AGR %) (Before COVID)
Figure No 100 : Europe Nuclear Medicine/Radiopharmaceuticals Market Forecast by Procedural Volume Assessment 2020-2030 (US$M, Global AGR %) (COVID - Scenario V)
Figure No 101 : Europe Nuclear Medicine/Radiopharmaceuticals Market Forecast by Procedural Volume Assessment 2020-2030 (US$M, Global AGR %) (COVID - Scenario U)
Figure No 102 : Europe Nuclear Medicine/Radiopharmaceuticals Market Forecast by Procedural Volume Assessment 2020-2030 (US$M, Global AGR %) (COVID - Scenario W)
Figure No 103 : Europe Nuclear Medicine/Radiopharmaceuticals Market Forecast by Procedural Volume Assessment 2020-2030 (US$M, Global AGR %) (COVID - Scenario L)
Figure No 104 : UK Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %) (Before COVID)
Figure No 105 : UK Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %) (COVID - Scenario V)
Figure No 106 : UK Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %) (COVID - Scenario U)
Figure No 107 : UK Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %) (COVID - Scenario W)
Figure No 108 : UK Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %) (COVID - Scenario L)
Figure No 109 : Germany Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %)
Figure No 110 : Germany Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %) (COVID - Scenario V)
Figure No 111 : Germany Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %) (COVID - Scenario U)
Figure No 112 : Germany Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %) (COVID - Scenario W)
Figure No 113 : Germany Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %) (COVID - Scenario L)
Figure No 114 : France Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %)
Figure No 115 : France Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %) (COVID - Scenario V)
Figure No 116 : France Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %) (COVID - Scenario U)
Figure No 117 : France Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %) (COVID - Scenario W)
Figure No 118 : France Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %) (COVID - Scenario L)
Figure No 119 : Rest of Europe Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %) (Before COVID)
Figure No 120 : Rest of Europe Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %) (COVID - Scenario V)
Figure No 121 : Rest of Europe Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %) (COVID - Scenario U)
Figure No 122 : Rest of Europe Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %) (COVID - Scenario W)
Figure No 123 : Rest of Europe Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %) (COVID - Scenario L)
Figure No 124 : Asia-Pacific Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M) (Before COVID)
Figure No 125 : Asia-Pacific Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M) (COVID - Scenario V)
Figure No 126 : Asia-Pacific Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M) (COVID - Scenario U)
Figure No 127 : Asia-Pacific Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M) (COVID - Scenario W)
Figure No 128 : Asia-Pacific Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M) (COVID - Scenario L)
Figure No 129 : Asia-Pacific Nuclear Medicine/Radiopharmaceuticals Market Forecast by Application 2020-2030 (US$M)
Figure No 130 : Asia-Pacific Nuclear Medicine/Radiopharmaceuticals Market Forecast by Application 2020-2030 (US$M) (COVID - Scenario V)
Figure No 131 : Asia-Pacific Nuclear Medicine/Radiopharmaceuticals Market Forecast by Application 2020-2030 (US$M) (COVID - Scenario U)
Figure No 132 : Asia-Pacific Nuclear Medicine/Radiopharmaceuticals Market Forecast by Application 2020-2030 (US$M) (COVID - Scenario W)
Figure No 133 : Asia-Pacific Nuclear Medicine/Radiopharmaceuticals Market Forecast by Application 2020-2030 (US$M) (COVID - Scenario L)
Figure No 134 : Asia-Pacific Nuclear Medicine/Radiopharmaceuticals Market Forecast by Procedural Volume Assessment 2020-2030 (US$M, AGR %) (Before COVID)
Figure No 135 : Asia-Pacific Nuclear Medicine/Radiopharmaceuticals Market Forecast by Procedural Volume Assessment 2020-2030 (US$M, Global AGR %) (COVID - Scenario V)
Figure No 136 : Asia-Pacific Nuclear Medicine/Radiopharmaceuticals Market Forecast by Procedural Volume Assessment 2020-2030 (US$M, Global AGR %) (COVID - Scenario U)
Figure No 137 : Asia-Pacific Nuclear Medicine/Radiopharmaceuticals Market Forecast by Procedural Volume Assessment 2020-2030 (US$M, Global AGR %) (COVID - Scenario W)
Figure No 138 : Asia-Pacific Nuclear Medicine/Radiopharmaceuticals Market Forecast by Procedural Volume Assessment 2020-2030 (US$M, Global AGR %) (COVID - Scenario L)
Figure No 139 : China Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %)
Figure No 140 : China Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %) (COVID - Scenario V)
Figure No 141 : China Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %) (COVID - Scenario U)
Figure No 142 : China Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %) (COVID - Scenario W)
Figure No 143 : China Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %) (COVID - Scenario L)
Figure No 144 : India Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %)
Figure No 145 : India Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %) (COVID - Scenario V)
Figure No 146 : India Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %) (COVID - Scenario U)
Figure No 147 : India Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %) (COVID - Scenario W)
Figure No 148 : India Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %) (COVID - Scenario L)
Figure No 149 : Japan Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %) (Before COVID)
Figure No 150 : Japan Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %) (COVID - Scenario V)
Figure No 151 : Japan Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %) (COVID - Scenario U)
Figure No 152 : Japan Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %) (COVID - Scenario W)
Figure No 153 : Japan Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %) (COVID - Scenario L)
Figure No 154 : Rest of APAC Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %) (Before COVID)
Figure No 155 : Rest of APAC Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %) (COVID - Scenario V)
Figure No 156 : Rest of APAC Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %) (COVID - Scenario U)
Figure No 157 : Rest of APAC Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %) (COVID - Scenario W)
Figure No 158 : Rest of APAC Nuclear Medicine/Radiopharmaceuticals Market Forecast 2020-2030 (US$M, AGR %) (COVID - Scenario L)
Figure No 159 : Middle East Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M) (Before COVID)
Figure No 160 : Middle East Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M) (COVID - Scenario V)
Figure No 161 : Middle East Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M) (COVID - Scenario U)
Figure No 162 : Middle East Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M) (COVID - Scenario W)
Figure No 163 : Middle East Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M) (COVID - Scenario L)
Figure No 164 : Middle East Nuclear Medicine/Radiopharmaceuticals Market Forecast by Application 2020-2030 (US$M) (Before COVID)
Figure No 165 : Middle East Nuclear Medicine/Radiopharmaceuticals Market Forecast by Application 2020-2030 (US$M) (COVID - Scenario V)
Figure No 166 : Middle East Nuclear Medicine/Radiopharmaceuticals Market Forecast by Application 2020-2030 (US$M) (COVID - Scenario U)
Figure No 167 : Middle East Nuclear Medicine/Radiopharmaceuticals Market Forecast by Application 2020-2030 (US$M) (COVID - Scenario W)
Figure No 168 : Middle East Nuclear Medicine/Radiopharmaceuticals Market Forecast by Application 2020-2030 (US$M) (COVID - Scenario L)
Figure No 169 : Latin America Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M)
Figure No 170 : Latin America Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M) (COVID - Scenario V)
Figure No 171 : Latin America Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M) (COVID - Scenario U)
Figure No 172 : Latin America Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M) (COVID - Scenario W)
Figure No 173 : Latin America Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M) (COVID - Scenario L)
Figure No 174 : Latin America Nuclear Medicine/Radiopharmaceuticals Market Forecast by Application 2020-2030 (US$M)
Figure No 175 : Latin America Nuclear Medicine/Radiopharmaceuticals Market Forecast by Application 2020-2030 (US$M) (COVID - Scenario V)
Figure No 176 : Latin America Nuclear Medicine/Radiopharmaceuticals Market Forecast by Application 2020-2030 (US$M) (COVID - Scenario U)
Figure No 177 : Latin America Nuclear Medicine/Radiopharmaceuticals Market Forecast by Application 2020-2030 (US$M) (COVID - Scenario W)
Figure No 178 : Latin America Nuclear Medicine/Radiopharmaceuticals Market Forecast by Application 2020-2030 (US$M) (COVID - Scenario L)
Figure No 179 : Africa Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M)
Figure No 180 : Africa Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M) (COVID - Scenario V)
Figure No 181 : Africa Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M) (COVID - Scenario U)
Figure No 182 : Africa Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M) (COVID - Scenario W)
Figure No 183 : Africa Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M) (COVID - Scenario L)
Figure No 184 : Africa Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M) (Before COVID)
Figure No 185 : Africa Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M) (COVID - Scenario V)
Figure No 186 : Africa Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M) (COVID - Scenario U)
Figure No 187 : Africa Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M) (COVID - Scenario W)
Figure No 188 : Africa Nuclear Medicine/Radiopharmaceuticals Market Forecast by Type 2020-2030 (US$M) (COVID - Scenario L)
Figure No 189 : Cardinal Health. (Total Company Sales 2016-2019 (US$mn, AGR %)
Figure No 190 : Cardinal Health. (Net Income 2016-2019 (US$mn, AGR %)
Figure No 191 : Curium (Total Company Sales 2016-2019 (US$mn, AGR %)
Figure No 192 : Curium (Net Income 2016-2019 (US$mn, AGR %)
Figure No 193 : GE Healthcare (Total Company Sales 2016-2019 (US$mn, AGR %)
Figure No 194 : GE Healthcare (Net Income 2016-2019 (US$mn, AGR %)
Figure No 195 : Lantheus Medical Imaging, Inc. (Total Company Sales 2016-2019 (US$mn, AGR %)
Figure No 196 : Lantheus Medical Imaging, Inc. (Net Income 2016-2019 (US$mn, AGR %))
Figure No 197 : Bayer AG Profile (Total Company Sales 2016-2019 (US$mn, AGR %)
Figure No 198 : Bayer AG Profile (Net Income 2016-2019 (US$mn, AGR %))
Figure No 199 : Bracco Imaging S.P.A Profile (CEO, HQ, Founded, Website)
Figure No 200 : Bracco Imaging S.P.A (Total Company Sales 2016-2019 (US$mn, AGR %))
Figure No 201 : Bracco Imaging S.P.A (Net Income 2016-2019 (US$mn, AGR %))
Figure No 202 :Nordion, Inc. (A Subsidiary of Sterigenics International) (Total Company Sales 2016-2019 (US$mn, AGR %))
Figure No 203 :Nordion, Inc. (A Subsidiary of Sterigenics International) (Net Income 2016-2019 (US$mn, AGR %))
Figure No 204 : Joint Stock Company Isotope (Jsc Isotope) (Total Company Sales 2016-2019 (US$mn, AGR %))
Figure No 205 : Joint Stock Company Isotope (Jsc Isotope) (Net Income 2016-2019 (US$mn, AGR %))
Figure No 206 : Joint Stock Company Isotope (Jsc Isotope) (Total Company Sales 2016-2019 (US$mn, AGR %))
Figure No 207 : Joint Stock Company Isotope (Jsc Isotope) (Net Income 2016-2019 (US$mn, AGR %))
Figure No 208 : Sinotau Pharmaceuticals Group (Total Company Sales 2016-2019 (US$mn, AGR %))
Figure No 209 : Sinotau Pharmaceuticals Group (Net Income 2016-2019 (US$mn, AGR %))
Companies Profiled in the Report
1. Eckert & Ziegler
2. Mallinckrodt
3. Curium Pharma
4. GE Healthcare
5. Jubilant Pharma. LLC
6. Bracco Imaging S.p.A
7. Nordion (Canada) Inc.
8. The Institute for Radioelements (IRE - IRE ELiT)
List of Companies Mentioned in the Report:
1. Actinium Pharmaceuticals, Inc
2. Alliance Medical
3. Alseres Pharmaceuticals, Inc
4. Bayer HealthCare Pharmaceuticals (Germany)
5. Bracco Diagnostics, Inc. (USA)
6. Cardinal Health, Inc. (USA)
7. GE Healthcare (UK)
8. Ion Beam Applications S.A (Belgium)
9. Immunomedics, Inc. (USA)
10. Jubilant Pharma (India)
11. Lantheus Medical Imaging Inc. (USA)
12. Medi-Radiopharma Ltd (Hungary)
13. Nordion, Inc. (Canada)
14. Peregrine Pharmaceuticals, Inc. (USA)
15. PETNET Solutions Inc. (USA)
16. Positron Corporation (USA)
17. Triad Isotopes, Inc. (USA)
18. Eckert & Ziegler
19. Mallinckrodt
20. Curium Pharma
21. GE Healthcare
22. Jubilant Pharma. LLC
23. Bracco Imaging S.p.A
24. Nordion (Canada) Inc.
25. The Institute for Radioelements (IRE - IRE ELiT)
26. Australian Nuclear Science & Technology Organization (ANSTO)
27. NTP Radioisotopes SOC Ltd.
28. Eczacibasi-Monrol
29. Lantheus Medical Imaging, Inc.
List of Organizations Mentioned in the Report:
• Society of Nuclear Medicine
• Food and drugs Administration
• American cancer society
• World health organization
• American Hospital Association (AHA)
• National Cancer Institute
• Canadian Association of Nuclear Medicine
Download sample pages
Complete the form below to download your free sample pages for Nuclear Medicine Market Report 2021-2031Download sample pages
Complete the form below to download your free sample pages for Nuclear Medicine Market Report 2021-2031Any specific country, geo region, market segment or specific company information?
Email us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
If so, please drop an email to Sara Peerun stating your chosen report title to sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.”
Dr Luz Chapa Azuella, Mexico
American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia
Visiongain Pharma
Visiongain Pharma
Visiongain PharmaLatest Pharma news
Visiongain Publishes Anti-infective Vaccines Market Report 2023-2033
The global Anti-infective Vaccines market is valued at US$48,360.4 million in 2023 and is projected to grow at a CAGR of 6.6% during the forecast period 2023-2033.
21 September 2023
Visiongain Publishes Contract Research Organisations (CROs) Market Report 2023-2033
The global Contract Research Organisations (CROs) market was valued at US$68.9 billion in 2023 and is projected to grow at a CAGR of 10.6% during the forecast period 2023-2033.
14 September 2023
Visiongain Publishes Stem Cell Therapy Contract Manufacturing Market Report 2023-2033
The global Stem Cell Therapy Contract Manufacturing market was valued at US$2,495.1 million in 2022 and is projected to grow at a CAGR of 12.4% during the forecast period 2023-2033.
13 September 2023
Visiongain Publishes Immuno-Oncology Clinical Trials Market Report 2023-2033
Immuno-Oncology Clinical Trials market is valued at US$6,849.8 million in 2023 and is projected to grow at a CAGR of 11.3% during the forecast period 2023-2033.
11 September 2023
